- Focus is on investing in and building vertically integrated portfolio in wholesale/retail, distribution and nutraceutical cannabis products for pets through legal cannabis ventures in North America
- Holdings include North Road Ventures, an emerging distributor of cultivated and manufactured cannabis products and holder of a pending ACMPR application for a license amendment to sell, distribute cannabis and related products
- Distribution strategy involves end-to-end, full cycle wholesale delivery
Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P), a vertically integrated cannabis company with strategic investments, continues its push to be ready for the green rush coming to Canada’s cannabis consumers. According to Statista, the medical marijuana market in Canada is projected to be worth C$1.1 billion in 2020 (http://ibn.fm/j1jGC). Canadian lawmakers are poised to open the adult-use recreational cannabis market by the fall of 2018, which is expected to make the nation’s combined medical/recreational cannabis market worth about $2.8 billion by 2020 (new CIBC report states that the market for Canadian adult use cannabis will approach $6.5 billion in retail sales by 2020) (http://ibn.fm/p8iCL).
Liberty Leaf and its wholly owned subsidiary, North Road Ventures, recently signed an agreement with Cannabis Compliance Inc. (“CCI”) to establish Good Manufacturing Practice (GMP)-compliant processes and procedures for producing its finished products (http://ibn.fm/GsomZ). North Road has an application pending with Health Canada for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license to distribute up to 7,500 kilos (16,500 pounds) of cannabis in its first year of operation.
Liberty Leaf expanded its portfolio in 2017 when it signed an agreement to develop up to four proprietary cannabidiol (“CBD”) formulations with ESEV Genetics R&D LLC, an American life sciences company researching cannabis and its role in medical solutions (http://ibn.fm/zPoWP). Together, Liberty Leaf and ESEV are working on a potentially very lucrative market – health and wellness for pets, specifically focusing on the efficacy of CBD pain management for canine osteoarthritis.
Liberty Leaf’s commitment to invest strategically in up-and-coming and established companies in the medicinal and recreational cannabis space is not relegated to Canada. The company is actively seeking to enter the various legal cannabis markets in North America, which Statista reports will bloom to more than $16 billion by 2020 (http://ibn.fm/EBWqV). A recent Deloitte report estimates that legal weed could be a $22.6 billion industry in Canada alone (http://ibn.fm/HXOln).
Liberty Leaf provides funding, management, HR resources and marketing expertise to help its investment holdings thrive and accelerate growth. Working relationships are formed with organizations engaged in research and development of cannabis uses, which also helps Liberty Leaf in its mission to expand and develop new markets.
For more information, visit the company’s website at www.LibLeaf.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.